NCT00767598View on ClinicalTrials.gov

The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

July 31, 2008

Conditions
Pharmacokinetics of Three PDE5IsHealthy SubjectsGenetic Polymorphic CYP3A5
Interventions
DRUG

phosphodiesterase type 5 inhibitor

single oral administration of 20mg vardenafil

DRUG

phosphodiesterase type 5 inhibitor

single oral administration of 100mg sildenafil

DRUG

phosphodiesterase type 5 inhibitor

single oral administration of 200mg udenafil

All Listed Sponsors
lead

Inje University

OTHER

NCT00767598 - The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects | Biotech Hunter | Biotech Hunter